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Abstract  Enoxaparin, a low-molecular-weight-heparin, 
is being used in hemodialysis patients despite a lack of 
guideline or manufacturer dose recommendations. Due to 
enoxaparin’s renal excretion, the possibility of accumulating 
anti-Xa concentrations in hemodialysis patients using 
enoxaparin creates a hemorrhagic risk, calling for more 
research. The objectives of this study are to determine the 
correlation between treatment dose enoxaparin use and 
anti-Xa concentrations within the defined therapeutic range 
in patients receiving chronic, scheduled hemodialysis to 
determine the degree of change in anti-Xa concentrations in 
those cases where a concentration was obtained before and 
after a specific hemodialysis session, and to determine if 
there is evidence of enoxaparin accumulation over the course 
of treatment. This was a retrospective cohort study. Patients 
that were admitted to Indiana University Health facilities in a 
two-year period were identified from a Cerner query for 
inclusion eligibility. Inclusion criteria involved patients that 
received therapeutic dose enoxaparin based on actual body 
weight on a once daily basis, maintained a scheduled 
hemodialysis regimen, and had an anti-Xa concentration 
obtained after at least one enoxaparin dose. Despite lacking 
statistical significance, the data collected from this study 
depicts trends which can be utilized to guide future studies. 
The results of this study suggest that hemodialysis does not 
effectively remove enoxaparin. 
Keywords  Enoxaparin, Hemodialysis, Treatment Dose, 
Correlation, Anti-Xa Concentration, Adult 
 
1. Introduction 
Enoxaparin is used increasingly for the treatment of 
thromboembolic disorders in patients undergoing 
hemodialysis (HD) despite the lack of manufacturer or 
guideline recommendations.[1] Enoxaparin offers a more 
reliable anticoagulant effect than unfractionated heparin 
(UFH) by having increased, more consistent bioavailability 
as well as a longer plasma half-life.[2-4] These 
pharmacological advantages have been found to improve 
clinical outcomes and are one of the reasons driving the need 
for additional studies involving treatment dose enoxaparin in 
hemodialysis.[4] 
Enoxaparin is a low-molecular-weight heparin with FDA 
approved indications for the treatment of acute deep vein 
thrombosis (DVT) with or without pulmonary embolism 
(PE), acute ST-segment elevation myocardial infarction 
(STEMI), unstable angina, and non ST-segment elevation 
myocardial infarction (STEMI). In addition to treatment, 
enoxaparin is also FDA approved for the prophylaxis of 
DVT in medical patients undergoing abdominal surgery, hip 
replacement surgery, or knee replacement surgery. 
Enoxaparin achieves anticoagulation by binding to 
antithrombin III, thus inhibiting clotting factors Xa and 
thrombin (IIa).[5] Due to enoxaparin’s selective nature of 
inhibiting factor Xa more than IIa, its pharmacokinetics and 
clinical outcomes may be monitored by measuring a 
patient’s anti-Xa concentrations. 
Compared to UFH, enoxaparin primarily undergoes renal 
elimination. Although routine monitoring of anti-Xa 
concentrations is not warranted in most patients without 
renal impairment who are receiving enoxaparin, the 
possibility of accumulating anti-Xa concentrations in 
patients with renal dysfunction poses a hemorrhagic risk and 
therefore is recommended.[6] The ideal time to draw anti-Xa 
concentrations in patients undergoing HD is at 5 and 24 
hours after enoxaparin administration as shown by 
Overholser [7] and colleagues. Other studies have estimated 
that it takes seven half-lives, approximately 35 hours, for 
renally impaired patients to reach steady state, meaning that 
the ideal time to measure anti-Xa concentrations would be 
after the second or third dose for patients receiving 
once-daily treatment.[8,9] The general target range of 
anti-Xa concentrations is 0.6-1 IU/mL for the 1 mg/kg every 
12 hour dosing regimen and 1-2 IU/mL for the 1.5 mg/kg 
every 24 hour dosing. Of note, the Indiana University Health 
laboratory uses a target range of 0.6-1.1 IU/mL.[10] 
Along with anti-Xa monitoring in patients with renal 
dysfunction, the 2012 CHEST guidelines recommend a 
treatment-dose reduction for a creatinine clearance ≤ 30 
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mL/min to 1 mg/kg every 24 hours based on actual body 
weight (ABW). However, due to lack of data in patients 
undergoing HD who are receiving enoxaparin, the guidelines 
suggest that enoxaparin should not be recommended in these 
patients, further reinforcing the fact that further study is 
needed. [11] 
Chan [12] and colleagues conducted a retrospective 
comparative effectiveness study in a large population of 
chronic maintenance dialysis patients initiated with 
subcutaneous injections of either enoxaparin or heparin for 
thromboprophylaxis. The study found that there was no 
statistically significant increase in serious bleeding or 
statistically significant decrease in efficacy as compared to 
subcutaneous heparin. This study combined with the 
majority of other trials and case reports available only 
examine prophylactic dose enoxaparin use.[13,14] The 
following study is the first to examine the potential for drug 
accumulation of full weight-based, treatment dose 
enoxaparin in end-stage renal disease (ESRD) patients 
receiving chronic, scheduled HD, and its influence on 
bleeding risk and mortality due to inadequate or excessive 
anticoagulation. 
2. Materials and Methods 
This was a retrospective cohort study. Patients were 
identified through a Cerner query of admissions over a two 
year span from June 1st, 2011 to May 31st, 2013. Any patient 
that was admitted to an intensive care unit, progressive care 
unit, or general medical ward at any of the following Indiana 
University Health facilities was eligible for inclusion: 
Methodist, University, North, West, and Arnett. Institutional 
ethical permission was obtained from these facilities. Our 
initial query identified twenty-three patients eligible for 
further evaluation. 
Patients were included if they received treatment dose 
enoxaparin at 1mg/kg based on ABW on a once daily basis, 
were on a scheduled HD regimen, and had an anti-Xa 
concentration obtained after at least one enoxaparin dose. 
Patients were required to have a legitimate medical 
indication for treatment dose enoxaparin and receipt of no 
other anticoagulant during admission. Exclusion criteria 
included prisoners, persons <18 years old, active pregnancy, 
anti-Xa concentration obtained more than 72 hours after last 
enoxaparin dose, and an enoxaparin dose <1mg/kg daily 
based on ABW. 
The primary study objectives were to determine the 
correlation between treatment dose enoxaparin use and 
anti-Xa concentrations within the defined therapeutic range 
(0.6-1.1 IU/mL) in patients receiving chronic, scheduled HD, 
to determine the degree of change in anti-Xa concentrations 
in those cases where a concentration was obtained before and 
after a specific hemodialysis session, and to determine if 
there is evidence of enoxaparin accumulation defined by an 
increase in anti-Xa concentrations over the course of 
treatment. Secondary study objectives were to assess 
in-hospital mortality, in-hospital mortality secondary to a 
venous thromboembolism (VTE)-related complication, and 
in-hospital mortality secondary to a major bleeding event. 
Seven patients were identified for inclusion from the 
Cerner query. There were sixteen patients that were excluded 
for eighteen reasons (Table 1). Descriptive statistics were 
used to present the data which included means and medians. 
Due to the small sample size and inherent lack of power, 
p-values were not able to be utilized. 
Baseline characteristics are presented in Table 2. 
Table 1.  Exclusions 
Exclusion Criteria Number of Exclusions 
Prisoners 0 
Active pregnancy 0 
<18 years old 0 
Anti-Xa concentration >72 hours after last enoxaparin dose 1 
Enoxaparin dose <1mg/kg q24h based on ABW 11 
Unscheduled hemodialysis 6 
TOTAL 18 
Table 2.  Baseline Characteristics 
 Range Median 
Age (years) 43 - 82 62 
LOS (days) 5 – 30 9 
ABW (kg) 64 – 98 77 
IBW (kg) 50 – 71 57 
BMI (kg/m2) 23.6 - 34 31 
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Six (85.7%) of the seven patients were female. The 
indications for treatment dose enoxaparin included six 
patients with a history of VTE and one patient with history of 
transient ischemic attack. All patients, given that they were 
on chronic, scheduled HD, were assumed to have ESRD with 
no remaining residual renal function. 
3. Results 
The results of this study appear in Table 3 and Table 4. Of 
the seven patients who met the pre-specified inclusion 
criteria, one patient (14.3%) was below, four patients (57.1%) 
were within, and two patients (28.6%) were above the 
desired anti-Xa range. The correlation coefficient between 
the daily enoxaparin dose and the first anti-Xa concentration 
was 0.42. While not statistically significant, this value 
indicates a “low” (defined as a correlation coefficient 
between 0.26 and 0.49) correlation between enoxaparin dose 
and increasing anti-Xa concentration. 
Of patients with anti-Xa concentrations above therapeutic 
range, a median of 9.5 doses of enoxaparin were 
administered before the concentration was drawn, compared 
with 1 dose in the subtherapeutic anti-Xa group, and 1.5 
doses in the therapeutic range anti-Xa group. Similarly, of 
the patients with anti-Xa concentrations above range, a 
median total enoxaparin exposure (number of doses 
multiplied by enoxaparin dose) of 905 mg was received, 
compared with 60 mg in the subtherapeutic anti-Xa group, 
and 140 mg for the within therapeutic range anti-Xa group.
Table 3.  Stratified Analysis of 1st Xa Concentrationa 
 Low (n=1) In Range (n=4) High (n=2) 
ABW (kg) 64.0 88.0 (77 - 98) 67.5 (66 - 69) 
Enoxaparin Daily Dose (mg) 60.0 90.0 (80 - 120) 85.0 (70 - 100) 
Number of Doses Prior to Concentration 1 1.5 (1 - 2) 9.5 (3 - 16) 
Total Enoxaparin Prior to Concentrationb 60.0 140 (100-160) 905 (210 - 1600) 
HD Sessions Prior to Concentration 1 (100%) 1 (25%) 2 (100%) 
a – Data presented as median (min, max) or count (percent) 
b – Calculated by multiplying enoxaparin daily dose by number of days received 
Table 4.  Individual Subject Characteristics Stratified by 1st Xa Concentration，Xa Concentration Below Therapeutic Range 
 Age (years) 
ABW 
(kg) 
Enoxaparin 
Daily Dose 
(mg) 
Number 
of Doses 
Prior 
Total 
Enoxaparin 
Priora 
Number 
of HD 
Prior 
Xa 
Concentration 
(IU/mL) 
Subject 1 82 64 60 1 60 1 0.1 
Xa Concentration Within Therapeutic Range 
 Age (years) 
ABW 
(kg) 
Enoxaparin 
Daily Dose 
(mg) 
Number 
of Doses 
Prior 
Total 
Enoxaparin 
Priora 
Number 
of HD 
Prior 
Xa 
Concentration 
(IU/mL) 
Subject 2 62 84 80 2 160 0 0.7 
Subject 3 63 77 80 2 160 1 0.6 
Subject 4 48 92 100 1 100 0 0.8 
Subject 5 53 98 120 1 120 0 0.8 
Xa Concentration Above Therapeutic Range 
 Age (years) 
ABW 
(kg) 
Enoxaparin 
Daily Dose 
(mg) 
Number 
of Doses 
Prior 
Total 
Enoxaparin 
Priora 
Number 
of HD 
Prior 
Xa 
Concentration 
(IU/mL) 
Subject 6 78 69 100 16 1600 7 1.2 
Subject 7 43 66 70 3 210 2 1.2 
a - Calculated by multiplying enoxaparin daily dose by number of days received 
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4. Discussion 
Due to the small number of patients in the study who met 
the inclusion criteria, the results of this study fail to achieve 
statistical significance. However, based on the collected data, 
several inferences can be made and utilized as 
hypothesis-generating ideas for future studies. 
One trend seen in the collected data is that the ABW of 
HD patients influenced the likelihood of having an anti-Xa 
concentration in range. Among those meeting the inclusion 
criteria of the study, it was found that the patients with higher 
body weights were more likely to have an anti-Xa 
concentration within the desired range. Two patients among 
the three lowest ABW’s (66 kg and 69 kg) also had the 
highest anti-Xa concentrations (both 1.2 units/mL). Since 
patients with lower body weights were receiving lower daily 
doses of enoxaparin compared with those with higher body 
weights, this trend may suggest altered distribution of 
enoxaparin in HD patients. Future studies should explore the 
possibility of using doses less than 1 mg/kg of enoxaparin in 
patients on HD who fall below a defined weight threshold. 
Another inference from the study findings involves 
enoxaparin accumulation in hemodialysis. This was 
demonstrated by higher anti-Xa concentrations occurring in 
patients with a higher cumulative number of enoxaparin 
doses as well as in patients who received more total 
enoxaparin exposure prior to the first anti-Xa concentration. 
While three patients who did not receive any HD prior to 
their first anti-Xa concentration still had an anti-Xa 
concentration within the target anti-Xa concentration, it 
should be noted that two of these patients had only received 
one dose of enoxaparin, and the other patient only received 
two doses. However, this observation tends to favor the idea 
that HD doesn’t increase the likelihood of having an in-range 
anti-Xa concentration. Extrapolating from this observation, 
the data suggests that HD does not effectively remove 
enoxaparin based on anti-Xa concentrations with regard to 
daily administration. Therefore, future research should 
compare pre-HD and post-HD anti-Xa concentrations to 
more fully and specifically demonstrate the hemodialysis 
effect on enoxaparin removal to determine if a lower 
treatment dose of enoxaparin or an extended dosing interval 
in this patient population may allow for adequate safety and 
effectiveness. 
5. Conclusions 
Despite lacking statistical significance, the data collected 
from this study provides trends which can be utilized to 
guide future evaluation. The influences on anti-Xa 
concentrations included patient body weight, number of 
enoxaparin doses received, and total enoxaparin exposure. 
The results of this study suggest that hemodialysis does not 
effectively remove enoxaparin. Future studies should 
compare pre-HD and post-HD anti-Xa concentrations to 
more completely define the influence of hemodialysis on 
enoxaparin clearance. 
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